SIRT2 and neoplasm: A recent study has shown that pharmacological inhibition of both SIRT1 and SIRT2 reduces cell viability by apoptosis in adult T-cell leukemia/lymphoma (ATL) cells and delays tumor growth through p53 activation in melanoma [8, 9].